SCHEMBL6325659

SCHEMBL6325659

NC1CCCC(Nc2n[nH]c(=O)c3cccnc23)C1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.48
ATAD2 Q6PL18 1/20 0.48
PIM1 P11309 7/20 0.43
JAK2 O60674 2/20 0.43
CDC7 O00311 1/20 0.43
DAPK3 O43293 1/20 0.43
ROCK2 O75116 1/20 0.43
PRKD3 O94806 1/20 0.43
MAP4K4 O95819 1/20 0.43
PAK4 O96013 1/20 0.43
PRKACA P17612 1/20 0.43
CDK2 P24941 1/20 0.43
FLT3 P36888 1/20 0.43
CSNK1A1 P48729 1/20 0.43
CDK8 P49336 1/20 0.43
CLK2 P49760 1/20 0.43
GSK3A P49840 1/20 0.43
GSK3B P49841 1/20 0.43
CDK7 P50613 1/20 0.43
CDK9 P50750 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6325411 1.00 BRD4 (0.48) BRD4ATAD2PIM1JAK2CDC7
SCHEMBL6325665 1.00 BRD4 (0.48) BRD4ATAD2PIM1JAK2CDC7
SCHEMBL6326315 0.91 BRD4 (0.48) BRD4ATAD2PIM1JAK2CDC7
SCHEMBL6327196 0.91 BRD4 (0.48) BRD4ATAD2PIM1JAK2CDC7
SCHEMBL6327187 0.91 BRD4 (0.48) BRD4ATAD2PIM1JAK2CDC7
SCHEMBL6327186 0.86 CD38 (0.41) JAK2ROCK2GRM4KAT2BULK1
SCHEMBL6323913 0.84 BRD4 (0.47) BRD4ATAD2PIM1ROCK2ULK1
SCHEMBL6324456 0.84 BRD4 (0.47) BRD4ATAD2PIM1ROCK2ULK1
SCHEMBL6324446 0.84 BRD4 (0.47) BRD4ATAD2PIM1ROCK2ULK1
SCHEMBL6324540 0.83 JAK3 (0.48) PIM1JAK2CDC7DAPK3ROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1423120-A4 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF ICOS CORP (US) 2005-12-28 EP disclosed
US-6924284-B2 PARP inhibitors ICOS CORPORATION (US) 2005-08-02 US disclosed
EP-1423120-A1 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF ICOS CORPORATION (US) 2004-06-02 EP disclosed
US-20040087588-A1 Parp inhibitors ICOS CORPORATION 2004-05-06 US disclosed
WO-2003015785-A1 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF ICOS CORPORATION (US) 2003-02-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040087588-A1 Parp inhibitors PARP1, PARP2, PARP11 BRD4 131/4885ATAD2 991/4885PIM1 654/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.